Foghorn Therapeutics, Inc. (FHTX)
1.87
-0.04
(-1.84%)
USD |
NASDAQ |
Nov 06, 16:00
1.865
0.00 (0.00%)
After-Hours: 20:00
Foghorn Therapeutics Research and Development Expense (Quarterly) : 18.32M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.32M |
| March 31, 2026 | 18.02M |
| December 31, 2025 | 21.24M |
| September 30, 2025 | 19.10M |
| June 30, 2025 | 20.89M |
| March 31, 2025 | 20.80M |
| December 31, 2024 | 19.75M |
| September 30, 2024 | 23.99M |
| June 30, 2024 | 23.00M |
| March 31, 2024 | 24.70M |
| December 31, 2023 | 23.35M |
| September 30, 2023 | 25.39M |
| June 30, 2023 | 28.37M |
| Date | Value |
|---|---|
| March 31, 2023 | 29.13M |
| December 31, 2022 | 27.36M |
| September 30, 2022 | 26.08M |
| June 30, 2022 | 25.16M |
| March 31, 2022 | 23.70M |
| December 31, 2021 | 21.65M |
| September 30, 2021 | 19.63M |
| June 30, 2021 | 17.86M |
| March 31, 2021 | 17.95M |
| December 31, 2020 | 15.91M |
| September 30, 2020 | 16.11M |
| June 30, 2020 | 13.37M |
| March 31, 2020 | 11.25M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Anavex Life Sciences Corp. | -4.705M |
| Vaxcyte, Inc. | 270.33M |
| Connect Biopharma Holdings Ltd. | 16.27M |
| Caribou Biosciences, Inc. | 21.35M |
| Arrowhead Pharmaceuticals, Inc. | 192.06M |